Mr. Xiangbo Jia has over 20 years of entrepreneurial and investment experience in the biopharmaceutical industry, specialising in corporate strategy and organisational management, and is familiar with the whole process of drug R&D, registration, health insurance, procurement, commercial distribution and hospital prescription management.
Mr Jia holds a Bachelor's degree from Nanjing University and a Master's degree in Management Engineering from the Australian National University.
Dr Yong Jiang Hei is the CEO of BioCity Biopharma responsible for leading the product R&D and the clinical development. He has proven track record in large global MNC (Amgen, Novartis) and biotech companies in China and the United States.
He has more than 20 years of product development experiences with strong expertise in oncology clinical development, in his career, he has successfully led clinical trials and global development of drugs in different modalities, including small molecules, mAb, BsAb and ADCs.
Dr Hei holds a Bachelor of Medicine, a Master of Science in Pharmacology, and a PhD in Pharmacology from the University of British Columbia, Canada.
Dr. Ivy Wang has a “Basic Research" and “ Clinical Medicine" multi-disciplinary background with over 15 years of research experience on signaling transduction pathways and cancer biology.
Dr. Wang has been working in the Department of Pathology at Case Western Reserve University and Cleveland Clinical，where she led a team to discover new mechanisms of inflammation and reversible tumour development.
In 2017, Dr Wang returned to China and co-founded BioCity, leading the company's product development, preclinical research and translational medicine research, and has led the team to obtain more than 20 IND approvals in CN and US.
Dr. Eric Rowinsky has over 25 years of global oncology drug clinical development experience. His professional career has been focused on the development and registration of new cancer therapeutics of all types. He has led teams that have registered more than twelve novel therapies for patients with advanced cancers worldwide.
He has served as board member or Chief Executive Officer of a number biotechnology companies, including Inspirna，Hummingbird and ImClone Systems.
Eric obtained his MD degree from Vanderbilt University and trained at University of California and Johns Hopkins. He received his undergraduate degree at New York University.
Prior to joining in Biocity she served as Chief Development Officer at Hummingbird Bioscience where she was responsible for leading the company’s clinical development programs and building out a US based team.
Leah received her PhD in Pharmacology from Duke University.
Dr. Timothy Yap is a Medical Oncologist and Physician-Scientist based at the University of Texas MD Anderson Cancer Center. He is an Associate Professor in the Department for Investigational Cancer Therapeutics (Phase I Program), and the Department of Thoracic/Head and Neck Medical Oncology. Dr. Yap is the Medical Director of the Institute for Applied Cancer Science, a drug discovery biopharmaceutical unit where drug discovery and clinical translation are seamlessly integrated. He is also the Associate Director of Translational Research in the Institute for Personalized Cancer Therapy, which is an integrated research and clinical trials program aimed at implementing personalized cancer therapy and improving patient outcomes. Prior to his current position, Dr. Yap was a Consultant Medical Oncologist at The Royal Marsden Hospital in London, UK and National Institute for Health Research BRC Clinician Scientist at The Institute of Cancer Research, London, UK.
Professor of Guangdong Provincial People’s Hospital, Guangdong Academy of Medical Sciences and Guangdong Lung Cancer Institute; lifetime Director and former Vice President of Guangdong General Hospital (GGH); and Member of Board of Directors of the International Association Study of Lung Cancer (IASLC).
Winner of Outstanding Science Achievement from IASLC (IASLC Paul A. Bunn, Jr. MD Scientific Award).
R&D Highlights: Prof. Wu is a pioneer of lung cancer research in China, gaining tremendous recognition from peers all over the world. He has committed himself to battling thoracic oncology at the front line.
CN
EN